10:03 AM EST - Oncolytics Biotech Inc. : Announced that the first patient has been treated in the Phase 1b trial MUK 11, studying REOLYSIN in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Revlimid® or Imnovid® as a rescue treatment in relapsing myeloma patients. Oncolytics Biotech Inc.
shares T.ONC are trading unchanged at $0.56.
